2 February 2026
Johnson & Johnson: ERLEADA® reduces death risk by 51% in mCSPC patients vs. darolutamide
Real-world study shows ERLEADA® offers significant survival benefits for mCSPC patients without docetaxel, supporting its use as a standard treatment.
